Reye’s Syndrome Treatment Market Analysis, Innovative trends and Global Forecast to 2023
Reye’s Syndrome is a rare disease that causes swelling of the liver and brain.
Increasing prevalence of influenza and rising teenage population are the major
drivers of the Reye’s Syndrome Treatment Market
. Moreover, increasing per capita
healthcare expenditure and developing biotechnology & pharmaceutical
industries within the developing economies across the world are estimated to
boost the market growth during the forecasted period. However, lack of
awareness, limited treatment options, and FDA approvals may restrain the market
growth during the forecast period.
Key Players:
·
Siemens
Healthcare Gmbh
·
CANON
MEDICAL SYSTEMS CORPORATION
·
Koninklijke
Philips N.V.
·
NeuroLogica
Corp
·
Sumitomo
Corporation
·
Pfizer
Inc
·
Novartis
AG
·
Merck
& C
·
AstraZeneca
·
Eli Lilly
and Company
·
Biocon
·
Ypsomed
·
BD
·
ARGON
MEDICAL
Segmentation:
·
The
global Reye’s syndrome market is segmented on the basis of diagnosis, treatment
and end users.
·
On the
basis of the diagnosis, the market is segmented into tests, biopsy, imaging,
and others. The test segment is sub-segmented into blood tests, urine tests,
and others. The biopsy segment is sub-segmented into liver biopsy, skin biopsy,
and others. The imaging segment is sub-segmented into computerized tomography
(CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and
others.
·
On the basis
of the treatment, the market is categorized into electrolytes and fluids,
corticosteroids, ammonia detoxicants, insulin, and others.
·
On the
basis of the end users, the market is segmented into hospitals & clinics,
research laboratories, diagnostic centers, and others.
Regional Analysis:
Europe holds the second largest
market for Reye’s syndrome. Availability of funds for research and government
support for research & development are the major drives for the growth of
the market within the region.
Asia Pacific is the fastest
growing region for the market due to the presence of continuously developing
economies. Moreover, growing the pharmaceutical sector and expanding healthcare
sector is estimated to drive the market growth within the region.
On the other hand, the Middle
East & Africa has the least share of the global Reye’s syndrome market.
Presence of poor economies and stringent government policies, especially within
the African region, are restraining the market growth within the region. A
majority of the market of this region is held by the Middle East.
Comments
Post a Comment